Article Menu
Need Help?
No Article Versions Notes Found
Cite
Frost, A.; Mross, K.; Steinbild, S.; Hedbom, S.; Unger, C.; Kaiser, R.; Trommeshauser, D.; Munzert, G. Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours. Curr. Oncol. 2012, 19, 28-35. https://doi.org/10.3747/co.19.866
Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G. Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours. Current Oncology. 2012; 19(1):28-35. https://doi.org/10.3747/co.19.866
Chicago/Turabian StyleFrost, A., K. Mross, S. Steinbild, S. Hedbom, C. Unger, R. Kaiser, D. Trommeshauser, and G. Munzert. 2012. "Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours" Current Oncology 19, no. 1: 28-35. https://doi.org/10.3747/co.19.866
APA StyleFrost, A., Mross, K., Steinbild, S., Hedbom, S., Unger, C., Kaiser, R., Trommeshauser, D., & Munzert, G. (2012). Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours. Current Oncology, 19(1), 28-35. https://doi.org/10.3747/co.19.866
